ArticleCureus2025
The Utility of a Y-tandem Applicator in a Patient With Stage IVA Locally Advanced Cervical Cancer in the Setting of a Bicornuate Uterus.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of a patient with a bicornuate unicollis uterus who developed International Federation of Gynecology and Obstetrics (FIGO) Stage IVA adenocarcinoma of the cervix invading the bladder neck, proximal urethra, upper vagina, and parametrium. The patient was treated with definitive chemoradiation therapy, including external beam radiation therapy (EBRT), brachytherapy, and weekly cisplatin infusions. Our patient required an interstitial brachytherapy boost, which was challenging to deliver due to her congenital anatomic anomaly. We were able to utilize the Syed-Neblett template to treat bilateral uteri using the holes in the template base as the entry points for brachytherapy catheters. In addition, a Y-tandem applicator was used to achieve the required angulation at the level of the cervix to reach both uterine walls. After completing both EBRT and brachytherapy, she was free of signs of disease on a follow-up visit approximately two months after treatment. The patient did not have any signs of locoregional disease six months later when she ultimately expired due to widespread pulmonary metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.